Randomized controlled trials (OXA+anti-EGFR vs OXA alone).
收藏Figshare2015-12-02 更新2026-04-29 收录
下载链接：
https://figshare.com/articles/dataset/_Randomized_controlled_trials_OXA_anti_EGFR_vs_OXA_alone_/204231
下载链接
链接失效反馈官方服务：
资源简介：
FOLFOX in COIN study: oxaliplatin 85 mg/m2 on day 1, L-folinic acid 175 mg or D,L-folinic acid 350 mg on day 1, FU 400 mg/m2 bolus and FU 2400 mg/m2 infusion over 46 h. Every 2 weeks.XELOX in COIN study: oxaliplatin 130 mg/m2 on day 1, capecitabine 850 mg/m2 twice a day on day 1 to 14. Every 3 weeks.Cetuximab in COIN study: an initial dose of 400 mg/m2 and thereafter 250 mg/m2. Every week.FLOX in NORDIC VII study: oxaliplatin 85 mg/m2 on day 1, FU 500 mg/m2 bolus +FA 60 mg/m2 bolus on days 1 and 2. Every 2 weeks.Cetuximab in NORDIC VII study: an initial dose of 400 mg/m2 and thereafter 250 mg/m2. Every week.FOLFOX4 in OPUS study: oxaliplatin 85 mg/m2 on day 1, leucovorin 200 mg/m2 followed by FU 400 mg/m2 bolus and 600 mg/m2 22-hour continuous infusion on days 1 and 2. Every 2 weeks.Cetuximab in OPUS study: an initial dose of 400 mg/m2 and thereafter 250 mg/m2. Every week.FOLFOX4 in PRIME study: oxaliplatin 85 mg/m2 on day 1, leucovorin 200 mg/m2 followed by FU 400 mg/m2 bolus and 600 mg/m2 22-hour continuous infusion on days 1 and 2. Every 2 weeks.Panitumumab in PRIME study: 6 mg/kg. Every 2 weeks.
创建时间：
2015-12-02
